Indicatrix has been shortlisted for an award at this year’s CPhI Pharma Awards in Frankfurt. The API Development Award looks for innovation in technologies, products, processes, and services for the development and manufacture of active pharmaceutical ingredients (APIs) including, but not limited to, synthesis, characterization, formulation, scale-up, software and database development, bulk manufacturing.
Since its inception in 2004, the CPHI Pharma Awards has celebrated cross-industry innovators making a contribution to driving the industry forward, though people, products and performance. The Awards welcomes entries from pharmaceutical and biopharmaceutical companies across the globe, engaged in the design, development, manufacture, production and distribution of both large and small molecule drug products.
This year, over 181 entries were received across the 10 categories which span all aspects of the industry, from API Development, Manufacturing Technology & Equipment and Digital Innovation to the prestigious CEO of the Year Award. All entries are reviewed in extensive detail by the CPhI expert panel of 17 Jury Members, who collectively bring decades of expertise from big pharma, consultancy, regulatory, market intelligence and academia.
Each entry receives a score from the Jury on specific criteria, which include; innovation, outcomes, features and purpose, problem-solving and competitive advantage. Top scoring entries in each category are shortlisted, and in the running to take home the trophy.
